These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30546956)

  • 21. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer.
    Worzfeld T; Pogge von Strandmann E; Huber M; Adhikary T; Wagner U; Reinartz S; Müller R
    Front Oncol; 2017; 7():24. PubMed ID: 28275576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium methyldithiocarbamate inhibits MAP kinase activation through toll-like receptor 4, alters cytokine production by mouse peritoneal macrophages, and suppresses innate immunity.
    Pruett SB; Zheng Q; Schwab C; Fan R
    Toxicol Sci; 2005 Sep; 87(1):75-85. PubMed ID: 15933225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time for a "Plan B" in Peritoneal Metastatic Disease.
    Tripodo C
    Cancer Res; 2019 Jan; 79(1):5-6. PubMed ID: 30602622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions.
    Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Pius-Sadowska E; Machaliński BB; Sompolska-Rzechuła A; Rzepka-Górska IA
    Onco Targets Ther; 2015; 8():471-85. PubMed ID: 25750541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trafficking and activation of murine natural killer cells: differing roles for IFN-gamma and IL-2.
    Sayers TJ; Mason LH; Wiltrout TA
    Cell Immunol; 1990 May; 127(2):311-26. PubMed ID: 2109662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
    Becker Y
    Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritoneal resident macrophages in tumor metastasis and immunotherapy.
    Zhang Y; Ouyang D; Chen YH; Xia H
    Front Cell Dev Biol; 2022; 10():948952. PubMed ID: 36035994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer.
    Kobayashi A; Tanizaki Y; Kimura A; Ishida Y; Nosaka M; Toujima S; Kuninaka Y; Minami S; Ino K; Kondo T
    Eur J Pharmacol; 2015 Nov; 766():63-75. PubMed ID: 26410360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sephadex induces eosinophil migration to the rat and mouse peritoneal cavity: involvement of mast cells, LTB4, TNF-alpha, IL-8 and PAF.
    Oliveira SH; Costa CH; Ferreira SH; Cunha FQ
    Inflamm Res; 2002 Mar; 51(3):144-53. PubMed ID: 12005205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cryo-thermal therapy inducing MI macrophage polarization created CXCL10 and IL-6-rich pro-inflammatory environment for CD4
    Liu P; Jia S; Lou Y; He K; Xu LX
    Int J Hyperthermia; 2019; 36(1):408-420. PubMed ID: 30892102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
    Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
    Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
    J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of cytokines on polymorphonuclear neutrophil infiltration in the mouse. Prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor.
    Sayers TJ; Wiltrout TA; Bull CA; Denn AC; Pilaro AM; Lokesh B
    J Immunol; 1988 Sep; 141(5):1670-7. PubMed ID: 3261759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of interleukin-3 does not affect the severity of local and systemic anaphylaxis but does enhance eosinophil infiltration in a mouse model of allergic peritonitis.
    Neel NF; Creasy BM; Rankin JN; Pierce EM; McCoy ME; Daner RH; Fowler JA; Daniel JC; Lantz CS
    Immunol Lett; 2004 Aug; 95(1):37-44. PubMed ID: 15325796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers.
    Gotlieb WH; Abrams JS; Watson JM; Velu TJ; Berek JS; Martínez-Maza O
    Cytokine; 1992 Sep; 4(5):385-90. PubMed ID: 1421000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.